Can we taper steroids without Flare-Ups? new study aims to find out

NCT ID NCT06072768

Recruiting now Knowledge-focused Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing two different ways to slowly reduce the dose of the steroid prednisone in people with rheumatoid arthritis. One group will taper over 15 days, the other over 150 days. Researchers want to see who develops symptoms or flare-ups during the taper, and why. The goal is to learn how to personalize steroid tapering to minimize side effects and keep arthritis under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: prednisone
What this could lead to: If successful, this could help doctors personalize steroid tapering plans for rheumatoid arthritis patients, reducing side effects while maintaining disease control.
What could go wrong: This is an early-phase study with only 200 participants, so results may not apply to everyone. The focus is on understanding responses, not on proving a new treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
VA Ann Arbor Healthcare System, Ann Arbor, MI
RECRUITING

Ann Arbor, Michigan, 48105-2303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.